Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Prenatal marijuana: Impact on infant neurobehavior, stress, & epigenetic mechanisms

Award Number: R01DA044504
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2017
PERIOD OF PERFORMANCE END DATE: 07/31/2025

Group Awards By:

View Award Description

Prenatal marijuana: Impact on infant neurobehavior, stress, & epigenetic mechanisms - Project Summary/Abstract Marijuana (cannabis sativa) is the most commonly used illicit substance by pregnant women in the US, with 1 in 12 pregnant women endorsing use and rates as high as 1 in 4 in poor, young, underserved mothers. With decreasing legal and medical sanctions, increasing availability, and increasing potency of US cannabis, there is high potential for increasing maternal use and fetal exposure. To our knowledge, there are currently no NIH-funded prospective human studies of prenatal cannabis use and offspring development or human studies of biological pathways linking prenatal cannabis and offspring development. We will conduct an intensive, prospective investigation of the specific effects of maternal prenatal cannabis use on infant neurobehavior including signs of withdrawal, infant stress response, and epigenetic regulation of endocannabinoid and glucocorticoid pathways. Central methodology involving prospective assessment of pregnant cannabis users (use ≥ 2X/week) and a tobacco-matched comparison group (n=125/group) across gestation followed by developmentally-sensitive measures of infant neurobehavior and stress response at 2 days, 1 and 6 months. An important innovation is our focus on epigenetic regulation of placenta endocannabinoid and glucocorticoid pathways as mediators of links between prenatal cannabis and infant neurobehavioral development. Our study also offers numerous innovations to ensure rigor, including one-on- one matching for tobacco use across cannabis and comparison groups, a propensity modeling approach to allow causal inference, exquisitely sensitive biomarkers and integrative classification of cannabis exposure, sophisticated, developmentally-sensitive measures of infant neurobehavior and stress response, and measurement of key alternative pathways. Our aims are: (1) to characterize effects of maternal cannabis use on infant neurobehavior including signs of withdrawal, (2) to characterize the impact of prenatal cannabis on infant glucocorticoid stress response over the first 6 months, (3) to characterize the impact of prenatal cannabis on epigenetic regulation of placenta glucocorticoid and endocannabinoid pathways, and (4) to test proposed placenta epigenetic pathways linking prenatal cannabis and infant neurobehavior. To our knowledge, the proposed study would be the first comprehensive investigation of the impact of prenatal cannabis use on infant neurobehavioral development as well as key plausible biological pathways. Our study is distinguished by its focus on a highly prevalent but understudied drug of abuse and innovative methods and novel biological pathways pioneered by our group. Results from the proposed study will provide critical data for obstetric providers and pregnant women, and will inform policy, regulations, and public health messaging regarding cannabis use by pregnant and reproductive age women. Results will also elucidate the earliest biomarkers of risk from prenatal cannabis exposure, with implications for identifying novel therapeutic targets to protect exposed offspring.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$1,072 )
2026	2021	THE MIRIAM HOSPITAL	164 SUMMIT AVE	PROVIDENCE	RI	02906	PROVIDENCE	USA	Drug Use and Addiction Research Programs	000	5	1/30/2026	NON-COMPETING CONTINUATION	-$1,072
														Subtotal = -$1,072

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	THE MIRIAM HOSPITAL	164 SUMMIT AVE	PROVIDENCE	RI	02906	PROVIDENCE	USA	Drug Use and Addiction Research Programs	000	5	8/22/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	THE MIRIAM HOSPITAL	164 SUMMIT AVE	PROVIDENCE	RI	02906	PROVIDENCE	USA	Drug Use and Addiction Research Programs	000	5	8/14/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $694,540 )
2021	2021	THE MIRIAM HOSPITAL	164 SUMMIT AVE	PROVIDENCE	RI	02906	PROVIDENCE	USA	Drug Use and Addiction Research Programs	000	5	7/21/2021	NON-COMPETING CONTINUATION	$694,540
														Subtotal = $694,540

Issue Date FY: 2020 ( Subtotal = $703,017 )
2020	2020	THE MIRIAM HOSPITAL	164 SUMMIT AVE	PROVIDENCE	RI	02906	PROVIDENCE	USA	Drug Use and Addiction Research Programs	000	4	7/27/2020	NON-COMPETING CONTINUATION	$703,017
														Subtotal = $703,017

Issue Date FY: 2019 ( Subtotal = $719,709 )
2019	2019	THE MIRIAM HOSPITAL	164 SUMMIT AVE	PROVIDENCE	RI	02906	PROVIDENCE	USA	Drug Use and Addiction Research Programs	000	3	7/24/2019	NON-COMPETING CONTINUATION	$719,709
														Subtotal = $719,709

Issue Date FY: 2018 ( Subtotal = $724,526 )
2018	2018	THE MIRIAM HOSPITAL	164 SUMMIT AVE	PROVIDENCE	RI	02906	PROVIDENCE	USA	Drug Use and Addiction Research Programs	000	2	7/19/2018	NON-COMPETING CONTINUATION	$724,526
														Subtotal = $724,526

Issue Date FY: 2017 ( Subtotal = $659,544 )
2017	2017	THE MIRIAM HOSPITAL	164 SUMMIT AVE	PROVIDENCE	RI	02906	PROVIDENCE	USA	Drug Use and Addiction Research Programs	000	1	8/29/2017	NEW	$659,544
														Subtotal = $659,544

Grand Total All Awards = $3,500,264

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Prenatal marijuana: Impact on infant neurobehavior, stress, & epigenetic mechanisms

Award Number: R01DA044504

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2017

PERIOD OF PERFORMANCE END DATE: 07/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer